complement protein C5 | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

13,652 results for “complement protein C5”

Astellas Withdraws European Application for Avacincaptad Pegol in Geographic Atrophy

Astellas Seeks First Japanese Approval for Geographic Atrophy Treatment with Avacincaptad Pegol

Newcastle Study Shows Safe Withdrawal of Eculizumab in Rare Kidney Disease, Saving NHS £4.2 Million Per Patient

AstraZeneca Advances Weight-Loss Drug Elecoglipron to Phase III as Company Targets $80B Revenue by 2030

CHMP Backs AstraZeneca's Klygefa (gefurulimab) for Generalised Myasthenia Gravis in the EU

Breakthrough Treatments Transform Landscape for Rare Hemolytic Anemias: From C5 Inhibitors to Novel Therapeutic Approaches

FDA Approves Fabhalta (Iptacopan) as First Oral Monotherapy for PNH

ImmunAbs Receives FDA Clearance for Phase 2 Trial of IM-101 Complement Inhibitor in Myasthenia Gravis

Iptacopan Shows Promise in Complement-Inhibitor-Naïve PNH Patients

Complement Inhibitors Show Promise in Diverse Clinical Trials

Page 1 of 637